Table 2.
Characteristics of the included studies.
| Author (year) | Total Participants | Participants | Participants | Follow-up, weeks | Primary endpoints |
|---|---|---|---|---|---|
| (# of FMR) | Treatment Group | Control Group | |||
| Velazquez, 2015 | 478 (415 FMR) | 239 | 239 | 48 | All-cause mortality |
| Asgar, 2016 | 92 (45 FMR) | 50 | 42 | 144 | All-cause mortality; Cost-effectiveness metrics |
| Armeni, 2016 | 383 (383 FMR) | 232 | 151 | 48 | Cost-effectiveness metrics |
| Giannini, 2016 | 120 (NR) | 60 | 60 | 48 | All-cause mortality |
| Geis, 2017 | 155 (124 FMR) | 86 | 69 | 48 | Cardiac remodeling metrics (LVEF, LVESD) |
| Obaida, 2018 | 304 (304 FMR) | 152 | 152 | 240 | Composite: all-cause mortality and HF hospitalizations |
| Kortlandt, 2018 | 863 (593 FMR) | 568 | 295 | 96 | All cause mortality |
| Stone, 2018 | 614 (614 FMR) | 302 | 312 | 96 | HF hospitalizations at 24 months, device related complications at 12 months |
FMR: functional mitral regurgitation; LVEF: left ventricular ejection fraction; LVESD: left ventricular end systolic diameter